How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey

Palandri, Francesca; Piciocchi, Alfonso; Stefano, Valerio De; Breccia, Massimo; Finazzi, Guido; Iurlo, Alessandra; Fazi, Paola; Soddu, Silvia; Martino, Bruno; Siragusa, Sergio; Albano, Francesco; Passamonti, Francesco; Vignetti, Marco; Vannucchi, Alessandro M.

doi:10.1038/s41375-020-0953-3

Cited by 15 publications

(23 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) survey published in Leukemia , most Italian haematologists declared to have temporarily adopted telephone or video consultations in patients with Philadelphia‐negative myeloproliferative neoplasms (MPNs) during the coronavirus disease 2019 (COVID‐19) pandemic. They also shared a certain propensity to expand the use of telemedicine after pandemic resolution 1 . MPNs includes essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (MF), and are chronic cancers with increased infectious risk compared to the normal population 2 , 3 .…”

Section: Figurementioning

confidence: 99%

“…We read with great interest the study by Fox et al 1 , reporting the outcomes of patients with SARS-CoV-2 receiving anti-cancer therapy. Data on COVID-19 in haematological patients remains limited indeed.…”

Section: Sars-cov-2 Persistence and Non-protective Immunity In Infectmentioning

confidence: 99%

“…They also shared a certain propensity to expand the use of telemedicine after pandemic resolution. 1 MPNs includes essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (MF), and are chronic cancers with increased infectious risk compared to the normal population. 2,3 Analogously, immune thrombocytopenia (ITP) is an auto-immune disorder that may require prolonged and severe immunosuppressive therapy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID‐19) pandemic: selection criteria and patients’ satisfaction

et al. 2020

Self Cite

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Section: Sars-cov-2 Persistence and Non-protective Immunity In Infectmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID‐19) pandemic: selection criteria and patients’ satisfaction

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…This infection has spread to Europe in February 2020 and, since then, thousands of studies addressing various aspects of COVID-19 have started and numerous clinical trials have been registered on ClinicalTrials.gov. However, there is limited information describing the presenting characteristics and outcomes of COVID-19 patients with myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) [4,5]. Natural history of MPN is marked by a high incidence of thrombosis and hemorrhagic complications and by a natural propensity to transform into overt MF and acute leukemia.…”

Section: Introductionmentioning

confidence: 99%

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

et al. 2021

Self Cite

View full text Add to dashboard Cite

We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19.

show abstract

“…Anyway, while using different timings and schedules, all the studies reported a clinical benefit within few days from treatment starts without major signs of ruxolitinib-associated toxicities (mainly due to the short treatment courses) underscoring the need of larger studies (phase 3 studies are ongoing) to confirm the activity of the drug in hyperinflamed COVID-19 patients regardless of the respiratory support they need. Ruxolitinib-related side effects, when present, could be managed and resolved through a fruitful and humble cooperation between oncohematologists familiar to the drug (130)(131)(132)(133) and clinicians from infectious disease, lung and intensive care units (118, 123-125, 127, 130, 134), without being misled by false convictions, lack of personal experience, overestimated toxicity (134) or by unethical conflicts of interests. In line with what recently highlighted in Lancet (135) and by La Roseé and colleagues (127), in this sad and difficult historical moment, patients deserve the best possible care and kind evaluation of new agents, communicating positive results immediately and promptly to the whole scientific community and translating new observational findings into structured (randomized) and methodologically correct clinical trials.…”

Section: Discussionmentioning

confidence: 99%

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

et al. 2021

View full text Add to dashboard Cite

Since SARS-CoV-2 outbreak in December 2019, world health-system has been severely impacted with increased hospitalization, Intensive-Care-Unit (ICU) access and high mortality rates, mostly due to severe acute respiratory failure and multi-organ failure. Excessive and uncontrolled release of proinflammatory cytokines (cytokine release/storm syndrome, CRS) have been linked to the development of these events. The recent advancements of immunotherapy for the treatment of hematologic and solid tumors shed light on many of the molecular mechanisms underlying this phenomenon, thus rendering desirable a multidisciplinary approach to improve COVID-19 patients’ outcome. Indeed, currently available therapeutic-strategies to overcome CRS, should be urgently evaluated for their capability of reducing COVID-19 mortality. Notably, COVID-19 shares different pathogenic aspects with acute graft-versus-host-disease (aGVHD), hemophagocytic-lymphohistiocytosis (HLH), myelofibrosis, and CAR-T-associated CRS. Specifically, similarly to aGVHD, an induced tissue damage (caused by the virus) leads to increased cytokine release (TNFα and IL-6) which in turn leads to exaggerated dendritic cells, macrophages (like in HLH) and lymphocytes (as in CAR-T) activation, immune-cells migration, and tissue-damage (including late-stage fibrosis, similar to myelofibrosis). Janus Kinase (JAK) signaling represents a molecular hub linking all these events, rendering JAK-inhibitors suitable to limit deleterious effects of an overwhelming inflammatory-response. Accordingly, ruxolitinib is the only selective JAK1 and JAK2-inhibitor approved for the treatment of myelofibrosis and aGVHD. Here, we discuss, from a molecular and hematological point of view, the rationale for targeting JAK signaling in the management of COVID-19 patients and report the clinical results of a patient admitted to ICU among the firsts to be treated with ruxolitinib in Italy.

show abstract

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey

Cited by 15 publications

References 9 publications

Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID‐19) pandemic: selection criteria and patients’ satisfaction

Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID‐19) pandemic: selection criteria and patients’ satisfaction

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

COVID-19: High-JAKing of the Inflammatory “Flight” by Ruxolitinib to Avoid the Cytokine Storm

Contact Info

Product

Resources

About